by | Mar 26, 2024 | Lupus Foundation of America, News & Events
CHARLOTTESVILLE, VA – March 26, 2024 – AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus. Revealed in the peer-reviewed journal Genome Medicine and being made...
by | Mar 25, 2024 | Lupus Foundation of America, News & Events
A new study examined the RUNX3 gene in people with systemic lupus erythematosus (SLE) and discovered increased methylation levels (or chemical changes) of the gene in blood cells. RUNX3 gene levels could be used as a potential biomarker for diagnosing SLE.Researchers...
by | Mar 20, 2024 | Lupus Foundation of America
Ashleigh’s heart holds a treasury of precious memories of her mother, Beryl, who bravely faced the challenges of lupus until her passing. Beryl’s journey with the disease began with subtle symptoms that gradually intensified, leading to her official...
by | Mar 15, 2024 | Lupus Foundation of America, News & Events
A new study finds that people with systemic lupus erythematosus-related thrombocytopenia (SLE-TP) who have antiphospholipid antibodies (aPLs) in their blood are more likely to have more severe disease, lower remission rates and higher relapse rates. aPLs are...
by | Mar 15, 2024 | Lupus Foundation of America, News & Events
To support the Phase 1b/2 study of IMPT-514, the California Institute for Regenerative Medicine (CIRM) awarded ImmPACT Bio an $8 million grant. In October, IMPT-514, an investigational therapy by ImmPACT Bio USA, Inc. was granted Fast Track designation by the U.S....
by | Mar 15, 2024 | Lupus Foundation of America, News & Events
The Food and Drug Administration (FDA) has approved Mallinckrodt’s supplemental New Drug Application (sNDA) for the Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector (SelfJect) for people with chronic and acute inflammatory and...